medigraphic.com
ISSN 0326-3428 (Print)
Órgano de difusión científica de la Asociación Nefrológica de Buenos Aires

2020, Number 2

<< Back Next >>

Rev Nefrol Dial Traspl 2020; 40 (2)

Systemic thrombotic microangiopathy associated with complement pathway mutations in living donor kidney transplant. Case report

Gutiérrez R, Fortunato RM, Vigliano C, Espinoza Á, Nava A, De Francesco J, Raffaele PM

Language: Spanish
References: 19
Page: 139-145
PDF size: 201.25 Kb.


ABSTRACT

Hemolytic uremic syndrome (HUS) is characterized by the presence of hemolytic anemia, thrombocytopenia and acute kidney injury. Although it is usually distinguished as typical or infectious and atypical, it is necessary to recognize clinical situations in which it is revealed, such as pregnancy, immediate postpartum period, tumors, transplantation, drugs, etc., i.e. clinical conditions that have been called complement-amplifying conditions.
Post-transplantation recurrence of atypical hemolytic uremic syndrome (aHUS) has been described in variable percentages in patients with mutations of factor H, factor B, factor I and C3, and thrombomodulin gene, in reports of isolated cases. We present the case of a patient with chronic kidney disease (CKD) secondary to renal agenesis, a preemptive recipient of a related living donor kidney, which presented renal graft dysfunction secondary to thrombotic microangiopathy, associated with neurological complications, hemorrhages, multiple organ dysfunction and death. The findings of the genetic and pathological autopsy study are described.


REFERENCES

  1. Brocklebank V, Wood KM, Kavanagh D. Thromboticmicroangiopathy and the kidney. Clin J Am Soc Nephrol. 2018;13(2):300-17. doi: 10.2215/CJN.00620117.

  2. Franchini M. Atypical hemolytic uremic syndrome:from diagnosis to treatment. Clin Chem Lab Med.2015;53(11):1679-88. doi: 10.1515/cclm-2015-0024.

  3. Laurence J, Haller H, Mannucci PM, Nangaku M,Praga M, Rodriguez de Cordoba S. Atypical hemolyticuremic syndrome (aHUS): essential aspects of anaccurate diagnosis. Clin Adv Hematol Oncol. 2016;Suppl11(11):2-15.

  4. Campistol JM, Arias M, Ariceta G, Blasco M, EspinosaL, Espinosa M, et al. An update for atypical haemolyticuraemic syndrome: diagnosis and treatment. Aconsensus document. Nefrología. 2015;35(5):421-47.doi: 10.1016/j.nefro.2015.07.005.

  5. Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G,Gamba S, et al. Relative role of genetic complementabnormalities in sporadic and familial aHUS and theirimpact on clinical phenotype. Clin J Am Soc Nephrol.2010;5(10):1844-59. doi: 10.2215/CJN.02210310.

  6. Caprioli J, Bettinaglio P, Zipfel PF, Amadei B, Daina E,Gamba S, et al. The molecular basis of familial hemolyticuremic syndrome: mutation analysis of factor H genereveals a hot spot in short consensus repeat 20. J Am SocNephrol. 2001;12(2):297-307.

  7. Sánchez-Corral P, Pérez-Caballero D, Huarte O,Simckes AM, Goicoechea E, López-Trascasa M, et al.Structural and functional characterization of factor Hmutations associated with atypical hemolytic uremicsyndrome. Am J Hum Genet. 2002;71(6):1285-95. doi:10.1086/344515.

  8. Zuber J, Le Quintrec M, Sberro-Soussan R, Loirat C,Frémeaux-Bacchi V, Legendre C. New insights intopostrenal transplant hemolytic uremic syndrome.Nat Rev Nephrol. 2011;7(1):23-35. doi: 10.1038/nrneph.2010.155.

  9. Rodríguez de Córdoba S, Hidalgo MS, Pinto S, TortajadaA. Genetics of atypical hemolytic uremic syndrome(aHUS). Semin Thromb Hemost. 2014;40(4):422-30.doi: 10.1055/s-0034-1375296.

  10. Skerka C, Józsi M, Zipfel PF, Dragon-Durey MA,Fremeaux-Bacchi V. Autoantibodies in haemolyticuraemic syndrome (HUS). Thromb Haemost.2009;101(2):227-32.

  11. Loirat C, Frémeaux-Bacchi V. Atypical hemolyticuremic syndrome. Orphanet J Rare Dis. 2011;6:60. doi:10.1186/1750-1172-6-60.

  12. Rodríguez de Córdoba S, Esparza-Gordillo J,Goicoechea de Jorge E, Lopez-Trascasa M, Sánchez-Corral P. The human complement factor H: functionalroles, genetic variations and disease associations.Mol Immunol. 2004;41(4):355-67. doi:10.1016/j.molimm.2004.02.005.

  13. Richards A, Buddles MR, Donne RL, Kaplan BS, KirkE, Venning MC, et al. Factor H mutations in hemolyticuremic syndrome cluster in exons 18-20, a domainimportant for host cell recognition. Am J Hum Genet.2001;68(2):485-90. doi: 10.1086/318203.

  14. Fakhouri F, Zuber J, Frémeaux-Bacchi V, LoiratC. Haemolytic uraemic syndrome. Lancet.2017;390(10095):681-96. doi: 10.1016/S0140-6736(17)30062-4.

  15. Fremeaux-Bacchi V, Kemp EJ, Goodship JA, Dragon-Durey MA, Strain L, Loirat C, et al. The developmentof atypical haemolytic-uraemic syndrome is influencedby susceptibility factors in factor H and membranecofactor protein: evidence from two independentcohorts. J Med Genet. 2005;42(11):852-6. doi: 10.1136/jmg.2005.030783.

  16. Le Quintrec M, Lionet A, Kamar N, Karras A, BarbierS, Buchler M, et al. Complement mutation-associatedde novo thrombotic microangiopathy following kidneytransplantation. Am J Transplant. 2008;8(8):1694-701.doi: 10.1111/j.1600-6143.2008.02297.x.

  17. Loirat C, Fremeaux-Bacchi V. Hemolytic uremicsyndrome recurrence after renal transplantation. PediatrTransplant. 2008;12(6):619-29. doi: 10.1111/j.1399-Recibido: 24 de octubre de 2019En su forma corregida: 31 de noviembre de 2019Aceptación final: 2 de enero de 2020Dr. Roberto GutiérrezUnidad Renal, Hospital Universitario Fundación Favaloro, Buenos Aires, ArgentinaORCID: 0000-0001-6075-0362e-mail: rggomez@ffavaloro.org3046.2008.00910.x.

  18. Delvaeye M, Noris M, De Vriese A, Esmon CT, EsmonNL, Ferrell G, et al. Thrombomodulin mutations inatypical hemolytic-uremic syndrome. N Engl J Med.2009;361(4):345-57. doi: 10.1056/NEJMoa0810739.

  19. Le Clech A, Simon-Tillaux N, Provôt F, Delmas Y,Vieira-Martins P, Limou S, et al. Atypical and secondaryhemolytic uremic syndromes have a distinct presentationand no common genetic risk factors. Kidney Int. 2019;95(6):1443-52. doi: 10.1016/j.kint.2019.01.023.




2020     |     www.medigraphic.com